Early assessment of endocan level as a predictor of remission status in acute leukemia patients

		Total no. = 45
Age	Mean ± SD	31.38 ± 10.36
Age	Range	14–56
Gender	Female	55.6% (n = 25)
Gender	Male	44.4% (n = 20)
Comorbidities	Negative	68.9% (n = 31)
Comorbidities	Positive	31.1% (n = 14)
Diagnosis	AML	44.4% (n = 20)
Diagnosis	ALL	51.1% (n = 23)
FAB (AML)	Mixed phenotypic	4.4% (n = 2)
	M1	25% (n = 5)
	M2	20% (n = 4)
	M3	20% (n = 4)
	M4	20% (n = 4)
	M5	15% (n = 3)
(ALL)	B ALL	47.8% (n = 11)
(ALL)	T ALL	52.2% (n = 12)

[i] Data indicate the demographic characteristics of studied patients, including the mean and standard deviation (SD) of patients' age, numbers (n), and percentage (%) of each gender, as well as comorbidities and diagnoses.

Table 2:

Comparison between initial endocan level and post-induction endocan.

		Initial	Post-induction	Test value	P-value	Sig.
Endocan	Median (IQR)	1950 (1637–2400)	385 (234–500)	−5.481≠	0.000***	HS***
Endocan	Range	1100–2400	150–1617	−5.481≠	0.000***	HS***

Data reveal the median values of initial and post-induction endocan levels.

*** P-value < 0.01: highly significant (HS).

Comparison between initial endocan level and post-induction endocan level among the examined patients.

Table 3:

Comparison of endocan levels in responders and non-responder patients.

Responders	Non-responders
No. = 40	No. = 5
Initial endocan	Median (IQR)	1915 (1582–2377.5)	2400 (2300–2400)	−1.841≠	0.066*	NS
Range	1100–2400	1885–2400
Post-induction endocan	Median (IQR)	342 (231.5–500)	496 (404–500)	−1.300≠	0.193*	NS
Range	150–1617	302–615

Data reveal the median values of initial and post-induction endocan levels in responders and non-responder patients.

* P-value > 0.05: non-significant (NS).

Table 4:

Endocan levels in responders versus non-responders AML and ALL patients.

Responders	Non-responders
No. = 18	No. = 2
Initial endocan	Median (IQR)	1898 (1566–2356)	2400 (2400–2400)	1.905^≠	0.057**	NS
Range	1100–2400	2400–2400
Post-induction endocan	Median (IQR)	388 (320–492)	399 (302–496)	0.126^≠	0.900*	NS
Range	202–900	302–496

Responders	Non-responders
No. = 20	No. = 3
Initial endocan	Median (IQR)	2251 (1663.5–2400)	2300 (1885–2400)	0.556^≠	0.578*	NS
Range	1150–2400	1885–2400
Post-induction endocan	Median (IQR)	246 (210–510.5)	500 (404–615)	1.233^≠	0.218*	NS
Range	150–1617	404–615

Data reveal the median values of initial and post-induction endocan levels in responders and non-responder patients in AML and ALL patients.

** P-value near 0.05: nearly significant (N.S.);

* P-value > 0.05: non-significant (NS).

Correlation between initial endocan level and LDH level among the studied patients.

The correlation between initial endocan and initial bone marrow blasts percentage among the studied patients.

Table 5:

Outcome of the examined patients.

		Total no. = 45
Mortality	Alive	86.7% (n = 39)
Mortality	Died	13.3% (n = 6)
OS (6 months)	Mean ± SD	3.87 ± 1.73
OS (6 months)	Range	1–6
Remission status	Responders	88.9% (n = 40)
Remission status	Non-responders	11.1% (n = 5)
PFS (6 months)	Mean ± SD	3.44 ± 1.73
PFS (6 months)	Range	1–6

[i] Data indicate the number and percentages (%) of deaths and responders and non-responder patients. Mean and standard deviation (SD) of overall survival (OS) and progression-free survival (PFS).

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/fco-2024-0019 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Submitted on: Aug 2, 2025

Accepted on: Nov 4, 2025

Published on: Mar 24, 2026

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Keywords:

Related subjects:

Haematology, oncology

© 2026 Rasha Magdy M Said, Tamer M. Ahmed, Rana Z. Abbas, Heba S. Agamy, Raed A. Shamkh, Basma S. M. Ali, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT

Early assessment of endocan level as a predictor of remission status in acute leukemia patients

Figures & Tables

Table 1:

Table 2:

Fig. (a):

Table 3:

Table 4:

Fig. (b):

Fig. (c):

Table 5:

Paradigm

My account